ERBB2 and non-small cell lung carcinoma: Despite encouraging results with breast carcinoma, no therapeutic benefit was observed of T-DM1 in the treatment of other cancer types, including pancreatic ductal carcinoma, non-small cell lung cancer (NSCLC), or OS, which generally express HER2 at lower levels (IHC1 1-2+) than HER2+ breast cancer [45,49,50,51,52].